Transcription profiling of skin from patients with moderate to severe atopic dermatitis before and after treatment with IL-4R? inhibitor dupilumab (REGN668/SAR231893)

ABSTRACT: Atopic dermatitis (AD) is the most common inflammatory skin disease, with high unmet need for new therapies that are safe for chronic use. Emerging data suggest that TH2-cytokines play important roles in a variety of allergic and atopic conditions, including asthma and AD. In early phase clinical trials, dupilumab (a fully human monoclonal antibody against IL-4R? that potently blocks IL-4 and IL-13 signaling) rapidly and markedly improved clinical measures in adults with either asthma (with elevated eosinophil counts) or moderate-to-severe AD. The pathomechanisms that may be impacted by IL-4/13 blockade in these disease settings have not yet been characterized in detail. Transcriptome analyses in pre- and post-treatment skin biopsies from patients with moderate-to-severe AD treated with

ORGANISM(S): Homo sapiens

SUBMITTER: Mayte Suarez-Farinas 

PROVIDER: E-GEOD-59294 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress